Press Releases

April 16, 2020

Chimeron Bio Appoints Eminent Virologist Dr. Jonathan Smith to its Scientific Advisory Board as it Initiates COVID-19 Vaccine Program

PHILADELPHIA–Chimeron Bio, a company pioneering a novel class of RNA therapeutics and vaccines announced the appointment of Dr. Jonathan (Jon) Smith to its Scientific Advisory Board. A distinguished virologist with experience spanning across   government, academia and biotech, Dr. Smith will advise the company on infectious diseases and vaccine development strategies, including the recently announced vaccine development program around COVID-19.

Currently the Chief Scientific Officer at VLP Therapeutics, Dr. Smith brings over 35 years of experience in virology, infectious diseases research and vaccine development with a focus on RNA-replicon vaccines. Dr. Smith was the former Chief of the Department of Virology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and co-founder of AlphaVax, Inc., a biotech focused on RNA vaccines for infectious diseases and cancer.

He has also held leadership positions at ClearPath Vaccines, PaxVax Inc., and Liquidia Technologies. Dr. Smith has led preclinical and translational programs for a range of infectious agents including Klebsiella, Pseudomonas, Cholerae, HIV, Influenza, Chikungunya, Anthrax, Dengue, Malaria and Zika. Dr. Smith has over 100 publications and multiple issued and pending patents in this field.

“The management and I are delighted to welcome Jon, an esteemed virologist and a seasoned industry leader to Chimeron Bio” said Jolly Mazumdar, founder and CEO of the company. “His extensive experience in the development of RNA-vectored vaccines and formulation manufacturing will be invaluable as we progress our COVID-19 vaccine program and our pipeline at large to the clinic.”

“RNA vaccines and therapeutics are indeed a next-generation medicine. Chimeron’s unique technology is poised to make a big impact and I am excited to be a part of this team and help them develop effective and affordable vaccines and therapeutics for infectious diseases and beyond” said Dr. Smith.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company is using its proprietary ChaESARTM platform to develop a pipeline in oncology, rare genetic disorders and infectious diseases.  For more information, visit www.chimeron.com.

Media Inquiries

Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?

Reach out to us at contact@chimeronbio.com today.

Follow Us